# Thymosin Alpha-1: research overview — Peptides Foundation > Thymosin alpha-1 (thymalfasin) is an immunomodulatory thymic peptide approved in over 35 countries but not the US. This page covers the clinical evidence — including the 2025 null sepsis trial — mechanism, and safety profile. Four decades of clinical literature, approval in dozens of countries, and a 2025 phase-3 trial that came back null. The evidence is real, mixed, and deserves to be read without the promotional spin. ## The short version Thymosin alpha-1 (scientific name thymalfasin) is a 28-amino-acid peptide originally isolated from thymus tissue. It works at the interface between the innate and adaptive immune systems — it has been studied as a treatment for chronic viral hepatitis, sepsis, cancer immunotherapy, and, more recently, COVID-19. It is approved as a drug in more than 35 countries under the trade name thymalfasin, but it is not FDA-approved for any indication in the United States. In the US, access is limited to investigational and compounding contexts. Here is the fact this desk thinks most people reading about thymosin alpha-1 deserve to see first: the largest, most rigorous trial ever conducted on it — a 2025 double-blind, randomized, placebo-controlled phase-3 trial (TESTS, n=1,106) — found **no** significant difference in 28-day all-cause mortality between thymosin alpha-1 and placebo in sepsis patients (HR 0.99; P=0.93) [13]. That null result does not erase decades of earlier data, but it is the highest-quality piece of evidence in the literature and it should anchor any reading of the rest. Note: thymosin alpha-1 is a separate compound from thymulin (a zinc-dependent thymic nonapeptide) and from TB-500/thymosin beta-4 (a WADA-prohibited actin-binding peptide). These are distinct molecules with different sequences and mechanisms. ## What it is Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide cleaved in vivo from the 113-amino-acid precursor prothymosin alpha. Its sequence (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) is highly acidic, with no aromatic residues and no disulfide bonds. The N-terminal acetylation is essential for biological activity; without it the peptide is inactive. The synthetic drug thymalfasin is sequence-identical. It is supplied as a lyophilized powder for subcutaneous injection. It should not be confused with thymosin beta-4 or its fragment TB-500, which have completely different sequences, different mechanisms, and different regulatory statuses. ## How it works Thymosin alpha-1 acts at the innate-adaptive immune interface. It signals through Toll-like receptors — notably TLR2 and TLR9 — on dendritic cells and monocytes, promoting their maturation, interleukin-12 production, and antigen presentation, which in turn drives T-cell maturation and Th1 polarization. In parallel, it can engage the IDO/tryptophan-catabolism pathway to generate regulatory T cells, giving it a dual character: it can restore effector immunity in states of immune suppression while also dampening hyperinflammation in states of immune overactivation. This bidirectional profile is mechanistically plausible and is offered as an explanation for why it has been studied across such different contexts — chronic viral infection (where boosting immunity is the goal), sepsis (where immune dysfunction is complex and bidirectional), and cancer immunotherapy (where turning 'cold' tumors 'hot' is the aim). Mechanism targets include: dendritic cells (TLR2/TLR9), T-cell maturation and differentiation, monocyte/macrophage function (HLA-DR, phagocytosis), and the innate-adaptive immune interface generally. ## What the research shows The literature spans four decades and multiple clinical settings. Evidence quality varies widely. **Sepsis — the best-quality evidence, and it is null:** The 2025 TESTS trial (Wu et al., BMJ; n=1,106; double-blind, placebo-controlled, phase 3; 22 centres) found no significant difference in 28-day all-cause mortality: HR 0.99 (95% CI 0.77–1.27; P=0.93) [13]. This is the definitive sepsis trial, and it is negative. Earlier smaller trials, including the ETASS trial (n=361, 2013), reported a borderline result: 26.0% vs 35.0% mortality (absolute reduction ~9 percentage points; log-rank P=0.049, but nonstratified P=0.062) [17] — a marginal finding that the larger TESTS trial did not replicate. **COVID-19 — retrospective data only:** A retrospective cohort (n=76 severe COVID-19 patients) reported lower mortality (11.11% vs 30.00%; P=0.044) and restoration of depleted/exhausted T cells, including reversal of PD-1 and Tim-3 overexpression on CD8+ T cells [15]. Retrospective data, single institution — hypothesis-generating, not confirmatory. **Cancer immunotherapy — adjuvant framing:** A 2019 review of thymosin alpha-1 in oncology described its use as an immunostimulatory adjuvant in combination protocols for melanoma, hepatocellular carcinoma, and lung cancer, with potential to enhance checkpoint-inhibitor efficacy and mitigate immune-related toxicity [16]. This is largely preclinical and observational in framing; no large phase-3 oncology RCT is in the references index. **General literature:** A 2020 comprehensive review characterized the standard clinical dosing range, noted approval in more than 35 countries, and described the safety profile as benign, dominated by local injection-site reactions [14]. The same review noted the trial base is heterogeneous, often China-centred, and frequently open-label or small. ## Reported effects, cautions, and safety **What research-use communities report (anecdotal, not clinical evidence):** Common positive reports include fewer or shorter colds over a season, faster recovery from illness, a general sense of immune resilience, and steadier daytime energy during recovery from chronic illness or post-viral fatigue. Many users also report noticing nothing at all — consistent with what one would expect from an immune modulator whose effects are biochemical rather than immediately perceptible. Negative anecdotal reports include mild injection-site redness and itching, occasional transient flu-like symptoms, and frustration about cost and supply access in the US. **Documented clinical cautions:** Injection-site reactions are the primary established adverse effect: local redness, itching, burning, or discomfort; large post-marketing surveillance across hundreds of thousands of treated patients identifies these as the dominant adverse events, with no documented organ toxicity at studied doses [14]. Theoretical cautions for autoimmune disease (Tα1 promotes effector immunity, which could worsen autoimmunity, even though it has regulatory arms) and for solid-organ transplant recipients (who are deliberately immunosuppressed) are noted in the literature, though systematic safety data in those populations are not available. **US regulatory status:** Not FDA-approved. Available in the US only in investigational or compounding contexts. Research-grade material lacks pharmaceutical-quality controls; identity, purity, and sterility are unverified. **Efficacy expectations:** Given that the highest-quality trial in the most studied acute-disease setting (sepsis, TESTS 2025) returned a null result [13], expectations should be calibrated accordingly, particularly outside the chronic-hepatitis setting where the historical evidence is historically strongest. ## Where it fits on this desk Thymosin alpha-1 is the most complicated read on this desk. It has the most international clinical approval of any peptide here without US FDA approval, a decades-long trial history, and a recent phase-3 result that calls its best-known acute-disease application into serious question. The chronic viral hepatitis evidence base predates these sepsis trials and is mechanistically different; the COVID-19 evidence is preliminary. None of this means the molecule is inert. It means the evidence is genuinely mixed, and anyone presenting it otherwise — in either direction — is not representing the literature accurately. --- An exacting literature digest: what the controlled trials actually found, weighed against what they didn't, and nothing added to fill the gap.